Drug intelligence / Profile preview

c-Nd2

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

c-Nd2 is an 111In-labeled murine/human chimeric monoclonal antibody developed for the preoperative clinical radioimmunodetection (RAID) of pancreatic cancer. It is administered intravenously and designed to specifically bind to antigens present on pancreatic cancer cells, allowing for their detection via scintigraphy using single photon emission computed tomography (SPECT) imaging. The drug has shown high sensitivity in detecting pancreatic cancer and liver metastasis, with no reported human anti-chimeric antibody (HACA) response or allergic reactions in tested patients.

Other names: 111In-labeled chimeric monoclonal antibody Nd2

Targets

MUC4 (Mucin-4)

Beyond the preview

Go deeper on c-Nd2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on c-Nd2.

Explore the full profile